IMI Stakeholder Forum 2017
Crowne Plaza Le Palace, Klimt room

8:30 – 9:00 Registration & welcome coffee

9:00 – 9:05 Welcome
Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)

9:05 – 9:30 Opening keynote
Nicola Bedlington, Secretary-General, European Patients’ Forum (EPF)

9:30 – 9:35 Breakout into parallel sessions, Klimt room

9:35 - 9:40 Introduction by Hugh Laverty, Head of Science Operations, IMI

9:40 – 10:10 Lecture | Human gut microbiome in health and disease
Dusko S. Ehrlich, Research Director Emeritus, INRA, French National Institute for Agricultural Research

10:10 – 10:30 Questions & answers

10:30 – 10:45 Regulatory challenges in the drug-food continuum
Yolanda Sanz, Professor of Research, Head of Microbial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology (IATA), National Research Council (CSIC), Spain; Member of the EFSA Panel on Dietetic Products, Nutrition and Allergies

10:45 – 11:00 Questions & answers, moderated by Maria Beatriz Da Silva Lima, Chair of the IMI Scientific Committee, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

11:00 – 11:20 Coffee break

11:20 – 11:50 Stakeholder discussion | The potential of collaborative research: accelerating breakthroughs and reducing fragmentation in microbiome research
Antoine Coutant, General Manager, Savencia Ingredients and Nutritional Solutions
Wulf Fischer-Knuppertz, CEO & Chairman, Biocrates Life Sciences
Marco Greco, President of the European Patients’ Forum (EPF), Past Chairman of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)
Dirk Hadrich, Scientific Officer, DG Research & Innovation, European Commission
Frank Møller Aarestrup, Professor, National Food Institute, Technical University of Denmark; Global Microbial Identifier
Kristof Van Emelen, CSO – Product Development, ProDigest
Vijay Yajnik, Medical Director, Clinical Science, GI TAU, Takeda
Chaired by Hugh Laverty, IMI
Themes under consideration for potential microbiome topics under an IMI Call for proposals

12:50 – 13:20
Large longitudinal studies with open access to metadata
Stefan Scherer, VP & Head Early Development, Strategy and Innovation US Oncology, Novartis
Questions & Answers

13:20 – 14:00
Lunch break

14:00 – 15:00
Bio-informatics solutions for strain level identification and analysis of hypothetical genes
Bio-banks of identifiable species with metadata, reference methods and standards
Alain Pluquet, Corporate VP, Chief Data Officer, bioMerieux
Questions & Answers

15:00 – 15:30
Translational studies addressing microbiome causality in human health and disease
Graham Somers, IMI Portfolio Director, GSK
Questions & Answers

15:30 – 16:00
Coffee break

16:00 – 17:00
Stakeholder Forum 2017 conclusions | Plenary Feedback from patient forum and microbiome forum
Elisabetta Vaudano, Principal Scientific Manager, IMI
Catherine Brett, External Relations Manager, IMI
Concluding remarks
Anders Olauson, Honorary President, EPF & Pierre Meulien, IMI

17:00
End of the event